Aravive, AstraZeneca Report Initiation Of Randomized Phase 1/2 Study Of AVB-500 In Combo With Durvalumab In Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Benzinga · 11/12/2019 14:08